Phase 2 IPF Study Now Enrolling
Learn more

News

Category: Uncategorized

Download Our Investor Presentation

Download our presentation

Download presentation

"*" indicates required fields

Calluna Pharma will use the contact details you provide to contact you with regards to offering further information, as well as to keep you updated on our latest developments. You may unsubscribe at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, please review our Privacy Policy.

Latest news

Latest News Press Releases
Calluna Pharma Announces U.S. FDA Orphan Drug Designation Granted to CAL101 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Oslo, Norway and Boston, USA, 31 October 2025: Calluna Pharma AS, a clinical stage biotechnology company pioneering first-in-class antibodies to treat...

Read more
Calluna Pharma Announces Initiation of Phase 2 AURORA Study of CAL101 for Idiopathic Pulmonary Fibrosis

Oslo, Norway and Boston, Massachusetts, 26 August 2025: Calluna Pharma AS, a clinical stage biotechnology company pioneering first-in-class antibodies to treat...

Read more
Calluna Announces Three Poster Presentations at the 2025 American Thoracic Society International Conference

Oslo, Norway and Boston, MA, 29 April 2025: Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to...

Read more